Literature DB >> 26454081

Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson's disease model.

Ning Xia1, Qian Zhang1, Shu Ting Wang1, Li Gu1, Hui Min Yang1, Li Liu1, Rachit Bakshi2, Hui Yang1, Hong Zhang3.   

Abstract

Glutamate excitotoxicity contributes to the development of Parkinson's disease (PD) and pharmacological blockade of metabotropic glutamate receptor 5 (mGluR5) has beneficial anti-akinetic effects in animal models of PD; however, the mechanism by which these antagonists alleviate PD symptoms is largely unknown. In our study, the effects of mGluR5 inhibition on DNA damage were investigated in a rotenone-induced model of PD. We first found that the selective mGluR5 antagonist, 2-methyl-6- (phenylethynyl) pyridine, prevented rotenone-induced DNA damage in MN9D dopaminergic neurons through a mechanism involving the downregulation of intracellular calcium release which was associated with a reduction in endoplasmic reticulum stress and reactive oxygen species (ROS)-related mitochondrial dysfunction. Interestingly, the ROS-related mitochondrial dysfunction was accompanied by an increase in expression of the antioxidant protein, Trx2. Treatment of cells with the calcium chelating agent 1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid or the ROS scavenger N-acetyl-L-cysteine, also reduced rotenone-induced DNA damage, while transfection of a dominant-negative form of Trx2 increased it. In addition, mGluR5 inhibition altered the expression profiles of proteins involved in DNA repair activity. Specifically, the expression of phosphorylated ERK (p-ERK) and CREB, as well as APE1 and Rad51 were elevated after rotenone stimulation and were subsequently downregulated following blockade of mGluR5. These findings were confirmed in vivo in a rotenone-induced rat model of PD. Inhibition of mGluR5 protected against neurotoxicity by mitigating oxidative stress-related DNA damage associated with 8-hydroxy-2'-deoxyguanosine production and also reduced p-ERK activity and Trx2 expression. These findings provide a novel link between mGluR5 and DNA damage in a model of PD, and reveal a potential mechanism by which mGluR5 mediates DNA damage in neurodegenerative diseases.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  8-OHdG, [Ca(2+)]i; DNA damage; ER; ERK; Metabotropic glutamate receptor 5; PD; Trx2

Mesh:

Substances:

Year:  2015        PMID: 26454081     DOI: 10.1016/j.freeradbiomed.2015.09.017

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  12 in total

1.  PDZ Scaffold Protein CAL Couples with Metabotropic Glutamate Receptor 5 to Protect Against Cell Apoptosis and Is a Potential Target in the Treatment of Parkinson's Disease.

Authors:  Wen Yuan Luo; Su Qian Xing; Ping Zhu; Chen Guang Zhang; Hui Min Yang; Nicholas Van Halm-Lutterodt; Li Gu; Hong Zhang
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

2.  Activated or Impaired: An Overview of DNA Repair in Neurodegenerative Diseases.

Authors:  Nan Qin; Anke Geng; Renhao Xue
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

3.  Blocked metabotropic glutamate receptor 5 enhances chemosensitivity in hepatocellular carcinoma and attenuates chemotoxicity in the normal liver by regulating DNA damage.

Authors:  Hui-Min Yang; Tian-Zhong Hou; Ya-Nan Zhang; Shu-Dong Zhao; Yong-Le Wu; Hong Zhang
Journal:  Cancer Gene Ther       Date:  2022-04-08       Impact factor: 5.854

4.  The involvement of the mGluR5-mediated JNK signaling pathway in rats with diabetic retinopathy.

Authors:  Yan-Ni Zhu; Guo-Jin Zuo; Qi Wang; Xiao-Ming Chen; Jin-Kui Cheng; Shu Zhang
Journal:  Int Ophthalmol       Date:  2019-01-03       Impact factor: 2.031

5.  Neonatal Rotenone Administration Induces Psychiatric Disorder-Like Behavior and Changes in Mitochondrial Biogenesis and Synaptic Proteins in Adulthood.

Authors:  Amanda Siena; Jéssica Mayumi Camargo Yuzawa; Aline Camargo Ramos; Elisandra Henrique; Mariana Dutra Brito; Mariana Bendlin Calvazara; Tatiana Rosado Rosenstock
Journal:  Mol Neurobiol       Date:  2021-02-19       Impact factor: 5.590

6.  Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic.

Authors:  Fenil Shah; Derek Logsdon; Richard A Messmann; Jill C Fehrenbacher; Melissa L Fishel; Mark R Kelley
Journal:  NPJ Precis Oncol       Date:  2017-06-08

Review 7.  Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration.

Authors:  Russell L Blaylock
Journal:  Surg Neurol Int       Date:  2017-04-26

Review 8.  Emerging preclinical pharmacological targets for Parkinson's disease.

Authors:  Sandeep Vasant More; Dong-Kug Choi
Journal:  Oncotarget       Date:  2016-05-17

9.  Lipid Metabolism is the common pathologic mechanism between Type 2 Diabetes Mellitus and Parkinson's disease.

Authors:  Xi Zhang; Yu Fan; Yuping Luo; Lingjing Jin; Siguang Li
Journal:  Int J Med Sci       Date:  2020-07-06       Impact factor: 3.738

Review 10.  Neurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate Receptors.

Authors:  Md Jakaria; Shin-Young Park; Md Ezazul Haque; Govindarajan Karthivashan; In-Su Kim; Palanivel Ganesan; Dong-Kug Choi
Journal:  Front Mol Neurosci       Date:  2018-08-29       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.